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Abstract
Background: The broad range in growth observed in short prepubertal children receiving the
same growth hormone (GH) dose is due to individual variation in GH responsiveness. This study
used a pharmaco-proteomic approach in order to identify novel biomarkers that discriminate
between short non-GH-deficient (GHD) children who show a good or poor growth response to
GH treatment.
A group of 32 prepubertal children with idiopathic short stature (ISS) were included in the study.
Children were classified on the basis of their first year growth velocity as either good (high
responders, n = 13; range, 0.9–1.3 standard deviation score (SDS) or poor (low responders, n =
19; range, 0.3–0.5 SDS) responders to GH treatment (33 μg/kg daily).
Serum protein expression profiles before, and after 1 year of GH treatment, were analyzed on a
weak cationic exchange array (CM10) using surface-enhanced laser desorption/ionisation time-of-
flight mass spectrometry (SELDI-TOF-MS).
Results: Changes in the intensity of two protein peaks (13.788 kDa and 17.139 kD) during the
study period allowed the correct classification of 82% of children as high and low responders,
respectively. The 13.788 kD peak, transthyretin, decreased in the high-responder group and
increased in the low-responder group during 1 year of GH treatment, whereas the 17.139 kDa
peak, apolipoprotein A-II (Apo A-II) decreased in the high-responder group and remained
unchanged in the low-responder group. These peaks were identified by the consistency of peak
pattern in the spectra, serum depletion experiments using specific antibodies and mass
spectrometry.
Conclusion: Our results suggest that transthyretin and apolipoprotein A-II may have a role in GH
sensitivity and could be used as markers to predict which short prepubertal children with ISS will
show a good or poor response to GH treatment.
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Background
Short stature is believed to be the result of many factors.
These include genetics, environment and many different
hormones. The growth hormone (GH)-dependent com-
ponent of growth during childhood is believed to result
from the integrated balance between GH secretion and
GH responsiveness in each child. Short stature in GH-defi-
cient (GHD) children arises as a result of poor GH secre-
tion, whereas short stature in children with idiopathic
short stature (ISS) may be due to differences in the degree
of GH responsiveness.
As we know that GH and insulin-like growth factor I (IGF-
I) play a major role in the regulation of postnatal growth,
most studies investigating GH responsiveness in patients
have involved assessments of mutations in single genes
involved in the GH/IGF-I axis [1,2]. However, very few
growth-related mutations have been identified by this
approach and it is clear that other, as yet unknown, factors
must be involved in responsiveness to GH treatment.
Prediction models for growth response to GH treatment,
a measure of GH responsiveness, suggest a role for auxo-
logical data, such as growth during infancy and childhood
[3], familial differences in height, height standard devia-
tion score (SDS) at treatment start and differences in mid-
parental height, as well as the responsiveness of the GH/
IGF-I axis [4-7]. Variables used in these prediction mod-
els, however, explain only around 50–70 % of the growth
response to GH.
This study explored the utility of a pharmaco-proteomic
approach for the identification of novel biomarkers that
allow the prediction of GH treatment response. For this
purpose we monitored changes in protein profiles using
surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF-MS). We analyzed
the expression of serum proteins before the start of GH
treatment and after 1 year of treatment in prepubertal chil-
dren with ISS and assessed differences in protein expres-
sion between patients with good and poor growth
responses to GH treatment. By using this approach two
nutrition proteins were identified that could be used to
discriminate between good and poor GH treatment
responders with respect to treatment response after 1 year
of treatment, and to a lower degree before treatment.
Subjects and methods
Study population
The procedure for study selection is shown in Figure 1.
From a group of 546 short (height below -2 SD [8]) pre-
pubertal children receiving GH treatment, the 40 children
with highest and the 40 children with lowest response on
the basis of their first year growth were selected. From this
group of 80 children, 51 children with ISS and a maxi-
mum peak of GH secretion (GHmax) on the arginine-insu-
lin tolerance test (AITT) > 5 μg/L were identified. Of this
subgroup, 19 were classified as high treatment responders
(first year height increase of 0.9–1.3 SDS), and 32 as low
treatment responders (0.1–0.5 SDS). Only patients for
whom two high quality mass spectra measurements were
available at each time point were included in further sta-
tistical analysis. The final study population included 37
children (14 high responders; 23 low responders) for
whom protein expression data were available before the
start of GH treatment and 32 children (13 high respond-
ers; 19 low responders) for whom protein expression data
were available after 1 year of GH treatment.
Auxological data for children for whom two high quality
spectra were available both before treatment and after 1
year are presented in Table 1.
All patients were of Caucasian origin and children with
dysmorphic syndromes or chronic diseases, were
excluded from the study. Data analysis included the fol-
lowing variables; GHmax  after AITT, spontaneous GH
secretion level over a 24 h period, IGF-I level, IGF-binding
protein 3 (IGFBP-3) level and leptin level [6]. The refer-
ences used for SDS calculations are [8] for height and
weigh and [9] for IGF-I. The children received daily injec-
tions of 33 μg/kg recombinant human GH produced from
the companies with GH products registered in Sweden.
Study design
Blood samples were taken at two different time-points.
The first sample was taken before the start of GH treat-
ment and the second 1 year after the start of GH treat-
ment. All samples were stored at -70°C for between 4 and
20 years and were not thawed until the time of analysis.
Ethics
The study was performed in agreement with the Helsinki
Declaration and approved by the Ethical Committee at
the Sahlgrenska Academy, University of Gothenburg (no
270-88 and 71516-05). Informed consent was obtained
from the parents of each child and from the child if old
enough.
SELDI-TOF serum protein profiling
Serum samples were thawed, denaturated and fraction-
ated using serum anion exchange beads according to pro-
tocols provided by Bio-Rad Laboratories, Hercules, CA.
Preliminary analyses were performed on all serum frac-
tions from four low and four high responders, using weak
anion-exchange (CM10), immobilized metal affinity cap-
ture (IMAC30) and reversed phase (H50) arrays (Bio-Rad
Laboratories) in order to determine which conditions
should be used for analysis of the whole study group.Proteome Science 2008, 6:35 http://www.proteomesci.com/content/6/1/35
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The procedure for study group selection Figure 1
The procedure for study group selection.
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Serum fraction 6 run on CM10 arrays was identified as the
most promising condition.
CM10 arrays were equilibrated twice with binding buffer
(150 μL; 100 mM NaAcetate, pH 4.0). 10 μL sample and
90 μL binding buffer were applied on spots and mixed at
room temperature using a DPC MicroMix 4 for 1 h for
protein binding. Duplicate samples were analyzed for
each patient at each time point. Arrays were washed three
times in binding buffer, rinsed twice in 1 mM HEPES, and
air-dried. 0.6 μL of a 50 % solution of sinapinic acid (Bio-
Rad Laboratories) in 0.5 % trifluoroacetic acid (Merck,
Darmstadt, Germany) and 50% acetonitril (Merck) was
then applied twice to each spot as a matrix.
Time-of-flight spectra were generated using a PBS IIc Pro-
teinChip reader (Bio-Rad Laboratories). Instrument set-
tings for analysis were optimized in the mass range of 2.3–
20.0 kDa and data were averaged from 240 transients for
each protocol. Samples were randomized and analyzed
concurrently within 1 week by the same operator in order
to minimize experimental variation. One reference serum
sample was randomly applied on each array. The mass
accuracy was calibrated in the molecular range of 5–18
kDa using external calibrators from Bio-Rad Laboratories.
The same calibration equation was used for all samples.
Data preprocessing
Data handling was performed using ProteinChip Data
Manager (Bio-Rad Laboratories). All spectra were base-
line-subtracted and normalized according to total ion cur-
rent, using an external normalization coefficient. Settings
for peak identification and clustering of peaks across mul-
tiple spectra were first pass signal-to-noise ratio (S/N) > 5
in 15% of all spectra and second pass S/N > 3, with a clus-
ter mass window 0.3% of the mass.
Spectra were visually inspected and data for patients were
excluded from further analysis if duplicated profiles dif-
fered or if the overall quality was low in one or both of the
spectra (i.e. high noise, overall low peak intensity or a nor-
malization factor exceeding 2). This process resulted in 33
valid peaks with mass/charge (m/z) values between 2.5
and 20.0 kDa. The average coefficient of variation (CV) for
the 17 peaks detected in all of the reference samples was
18% (11–31%).
Table 1: Auxological data for the children included in the analysis, from whom high-quality spectra were available both before and 
after 1 year of GH treatment.
High-responder group Low-responder group
Variables Median Min Max N Median Min Max N
At birth
Gestational age (weeks) 39 38 42 13 39 37 471 19
Height SDS --1.49 --3.94 1.34 13 --1.93 --3.82 --0.18 19
Weight SDS --1.90 --2.77 1.59 13 --1.20 --2.89 0.80 19
Pretreatment
Delta height SDS during pretreatment yr --2.84 --3.57 --2.24 11 --2.88 --4.13 --2.17 18
At GH start
Gender (min = girls, max = boys) 2 11 13 4 15 19
AGA/SGA (min = AGA, max = SGA) 8 5 13 10 9 19
*Age (yrs) 5.84 3.90 10.53 13 9.31 3.32 11.96 19
Height SDS --2.66 --3.84 --2.04 13 --2.84 --4.33 --1.59 19
Weight SDS --2.51 --3.56 --1.72 13 --2.20 --4.11 --1.15 19
Father height SDS --0.98 --1.59 2.12 13 --0.98 --2.95 0.85 19
Mother height SDS --0.80 --2.04 1.15 13 --1.58 --2.93 0.56 19
MPHSDS --0.54 --1.81 0.55 13 --1.21 --2.46 0.63 19
GHmax AITT 21.86 20.20 48.07 13 28.75 18.20 63.86 17
*GHmax 24 h 23.81 23.40 39.68 6 53.71 27.12 87.78 12
Diff MPH SDS --2.13 --3.73 --0.85 13 --1.67 --2.81 --0.34 19
IGF-I SDS --1.02 --2.56 1.34 11 --0.98 --4.62 1.08 17
*Leptin (ng/mL) 3.96 2.14 5.93 12 2.40 1.21 4.30 17
During treatment
*GH dose (U/kg/day) 0.11 0.09 0.12 13 0.10 0.09 0.11 19
*Change in height SDS 1st yr 0.96 0.89 1.26 13 0.42 0.25 0.51 19
AITT, arginine – insulin tolerance test; GHmax, maximum peak of GH secretion; IGF-I, insulin-like growth factor I; AGA, appropriate for gestational 
age; SGA, small for gestational age; MPH midparental height; diffMPHSDS, difference in height SDS of the child versus its midparental height SDS
0.1 U GH/kg/day = 33 μg/kg/day
The references used for SDS calculations are [8] for height and weigh and [9] for IGF-I.
* indicates p < 0.05 between groups.Proteome Science 2008, 6:35 http://www.proteomesci.com/content/6/1/35
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Statistics
To identify peaks of potential interest, serum proteomic
profiles for the high- and low-responder groups were
compared before and after 1 year of treatment. Changes in
maximum protein peak intensities during 1 year of GH
treatment were also assessed.
Initially, ProteinChip Data Manager was used for calcula-
tion of p-values for single peaks. For paired statistics, Pro-
teinChip Data Manager compared the mean values of
peak clusters, by sample group, using the Wilcoxon
signed-rank test.
Multivariate statistics
Subsequent multivariate data analysis was performed
with Matlab software (version 7.3.0 R2006b, The Math-
works) on the mean intensity levels of the duplicate sam-
ples.
Cross-validated stepwise regression
Using stepwise regression, subsets of peaks were selected
and assessed to examine the difference between high and
low responders (before and 1 year after GH treatment) or
the differences between pre-treatment and 1 year of GH
treatment. Varying the input parameters of the stepwise
regression generated a set of potential regression models.
Only models where the final number of peaks selected
was not more than 10% of the total number of samples
were studied further. The best regression model was
selected by tenfold cross-validation, where the tenfold
cross-validation was repeated ten times in order to obtain
more reliable estimates of the cross-validated R2.
Relationships with other variables
The procedures described above were also applied to
explore the relationships between the peaks, instrumental
and clinical variables, such as early growth data, parental
height, IGF-I levels, leptin levels and the predicted
response from published GH prediction models.
Rotated two-component PLS regression/PLS discriminant 
analysis
Partial least squares (PLS) regression was used to explore
the relationships between the most predictive protein
peaks. We selected between 2 and 15 of the peaks that had
the highest correlation with the response variable and
used the binary high/low-responder classification or the
observed delta height SD scores after 1 year of GH treat-
ment as the response variable. A two-component PLS
regression was computed with two latent variables and
then rotated in such a way that the first rotated compo-
nent gave the ordinary least-squares regression on the
response variable and the second rotated component had
maximum residual variance for the predictor variables. If
the response variable is a binary variable, the PLS regres-
sion is comparable to a PLS-discriminant analysis (PLS-
DA), and in that case the first rotated component will give
the discrimination function. The R2 and the tenfold cross-
validated R2 values of the PLS regression are presented. For
the PLS-DA we also present the cross-validated correct rate
of classification in percentage (CVcorrect).
Analysis of systematic errors
Principal component analysis (PCA), PLS regression and
stepwise regression were used to analyze the impact of sys-
tematic errors on the results. For a few peaks there was a
weak linear relationship between peak intensity and stor-
age time. The influence of storage time on peak intensity
was corrected for using linear regression. Two peaks (m/z
values of 4.149 and 4.182 kDa) had a non-linear relation-
ship with storage time and were therefore excluded from
further data analysis.
Protein identification
Immunodepletion
Fractionated serum was immunodepleted using rabbit
anti-transthyretin (DAKO, Glostrup, Denmark) or anti-
apolipoprotein A-II (GenScript Corporation, Piscataway,
NJ) antibodies and dynabeads (Invitrogen, Carlbad, CA)
coated with anti-rabbit IgG. Dynabeads were washed
twice in 1 mL PBS (PAA Laboratories GmbH, Pasching,
Austria) and resolved in 0.5 mL PBS. 4 μg of antibody was
added per 50 μL dynabeads and incubated over night at
4°C on a rotation mixer (REAX 2, Heidolph, Schwabach,
Germany). Unbound antibodies were removed by wash-
ing twice in 1 mL PBS. The beads were resolved in 50 μL
PBS, and 20 μL of fractionated serum was then added fol-
lowed by incubation for 1 h at 4°C on a rotation mixer,
followed by two washes in 1 mL PBS. The depleted serum
was analyzed on CM10 arrays.
In-gel protein digestion
In-gel protein digestion with trypsin was, with some
minor modifications, performed as described by
Shevchenko et al. [10].
Nanoflow liquid chromatography/tandem MS (LC -MS/MS) Fourier 
transform ion cyclotron MS (FT/ICR MS)
Two-microliter sample injections were made with an
HTC-PAL autosampler (CTC Analytics AG, Zwingen, Swit-
zerland) connected to an Agilent 1100 binary pump (Agi-
lent Technologies, Palo Alto, CA, USA). The peptides were
trapped on a precolumn (45 × 0.075 mm i.d.) packed
with 3 μm C18-bonded particles and separated on a
reversed phase column, 200 × 0.050 mm. Both columns
are packed in-house with 3 μm Reprosil-Pur C18-AQ par-
ticles. A 40 min gradient 10–50% CH3CN in 0.2% COOH
was used for separation of the peptides.Proteome Science 2008, 6:35 http://www.proteomesci.com/content/6/1/35
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Nanoflow LC-MS/MS was performed on a hybrid linear
ion trap-FTICR mass spectrometer (LTQ-FT, Thermo Elec-
tron, Bremen, Germany). The spectrometer was operated
in data-dependent mode, automatically switching to MS/
MS mode. MS-spectra were acquired in the FTICR, while
MS/MS-spectra were acquired in the LTQ-trap. All the tan-
dem mass spectra were searched by MASCOT (Matrix Sci-
ence, London, UK) against the SwissProt 5.16 database.
The search parameters were set to: MS accuracy 5 ppm,
MS/MS accuracy 0.5 Da, one missed cleavage by trypsin
allowed, fixed propionamide modification of cysteine
and variable modification of oxidized methionine.
Results
Changes in protein expression profile in response to GH 
during the first year of treatment
In all data analyses, both the binary variable low versus
high responder, and the continuous variable first year
delta height SD, were used as outcome variables. This pro-
duced similar results. For a number of the peaks identi-
fied, we found that the change in peak intensity during the
first year of treatment correlated with GH responsiveness.
Thus, these peaks could be used as biomarkers for classi-
fying patients as good or poor responders to GH treat-
ment. Using information from between 2 and 15 peaks
resulted in an R2 in the range of 0.47–0.51 and a CVcorrect
in the range of 82–64 % (Table 2, Figure 2). The 15 most
predictive peaks identified by the rotated two-component
PLS regression analysis are shown in Table 2. Using infor-
mation on the intensity changes of the peaks with m/z val-
ues of 13.877 and 17.139 kDa, 82% of the study subjects
could be correctly classified as low or high responders,
respectively. Including more than two peaks in the analy-
sis did not improve classification.
The middle panel in Figure 2A shows that auxological
data correlated with changes in the maximum intensity of
the 13.877 kDa peak, and that variables associated with
the GH/IGF-I axis, including IGF-I levels, leptin levels and
GHmax24 h, correlated with changes in the intensity of the
17.139 kDa peak. Mean spectra of the 13.877 and 17.139
kDa peaks for high and low responders were created (Fig-
ure 3). As shown in the figure, in the high-responder
group the intensities of both peaks decreased during the
first year of GH treatment. In the low-responder group,
the intensity of the 13.877 kDa peak was increased during
the first year of treatment, whereas the intensity of the
17.139 kDa peak was unchanged during treatment.
Protein profiles before start of GH treatment
We were then interested to explore whether protein
expression profiles could also be used to predict the
Table 2: The most predictive peaks identified by rotated two-component PLS regression analysis.
Number of peaks R2 CVcorrect First year growth hormone responsiveness Peak m/z value (kDa)
15 0.51 64 17.584, 17.383, 17.256, 17.139, 13.788, 9.127, 8.820, 8.689, 6.833, 6.626, 6.474, 6.428, 4.401, 3.212 and 
3.311
5 0.47 76 13.877, 17.139, 17.256, 17.584 and 6.428
4 0.47 78 13.877, 17.139, 17.256 and 17.584
3 0.47 81 13.877, 17.139 and 17.256
2 0.47 82 13.877 and 17.139
Before treatment
15 0.32 59 3.311, 4.401, 4.463, 7.010, 8.689, 8.820, 9.709, 13.877, 14.040, 14.142, 15.132, 17.139, 17.256, 17.584, 
28.067
5 0.23 63 14.040, 14.142, 17.139, 17.256, 28.067
4 0.24 65 14.142, 17.139, 17.256, 28.067
3 0.32 74 9.361, 14.040, 17.256
2 0.17 59 17.139, 17.256
The most predictive peaks identified by rotated two-component PLS regression analysis when 2, 3, 4, 5 and 15 peaks were included in the analysis. 
For each model the R2-value and correct rate of classification (CVcorrect) are presented. It is the peak intensity changes during the first year of GH 
treatment that are used in the analyses.Proteome Science 2008, 6:35 http://www.proteomesci.com/content/6/1/35
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growth response and level of GH responsiveness before
start of treatment. Using the same statistical methods as
described above, we found that information from
between 2 and 15 peaks resulted in an R2 in the range of
0.17–0.32 and a CVcorrect in the range of 74–59 % (Table
2). The best model for prediction of GH response before
start of treatment was obtained when the 3 peaks with m/
z values of 9.361, 14.040 and 17.256 kDa were included
in the model (R2 = 0.32, CVcorrect = 0.74).
Identification of selected peaks
After identifying specific peaks that could be used to dis-
criminate between high and low responders to GH treat-
ment, we wanted to identify the proteins representing the
Computerized selection of the most predictive peaks for discrimination between high and low responders to GH treatment Figure 2
Computerized selection of the most predictive peaks for discrimination between high and low responders to 
GH treatment. The figure shows the rotated partial least squares regression using the 2 (A) and 5 (B) most predictive pro-
tein peaks. In all analyses, changes in the peak intensity during the first year of GH treatment are used. The left panels demon-
strate which peaks are selected and the degree to which they correlate with the first dimension (low/high response on the x-
axis). The first dimension (Predicted response) is a weighted sum of the selected peaks and gives the best prediction of the 
binary low/high-response variable. A positive correlation with the first dimension indicates that the maximum peak intensity 
has increased more for the high responders than low responders during 1 year of treatment, whereas a negative correlation 
indicates that the maximum peak intensity has increased more for the low responders. The second dimension is a residual 
component. Residual, in the sense that it has no correlation with the response variable and, component, in the sense that it of 
all the selected predictor variables it explains the maximum variance. The use of this dimension facilitates the discovery of clus-
ters of related peaks, or peaks conveying comparable information. In the middle panels, correlations of dimensions 1 and 2 
with phenotype are shown. The right panels illustrate the discrimination of the individual low and high responders using the 
selected peaks. Low responders are shown as triangles; high responders as circles.
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most predictive peaks. From the consistency of the peak
pattern in the spectra, the peaks with m/z values around
14 kDa were recognized as different posttranslational
modified forms of transthyretin; the 13.877 kDa peak was
recognized as the unmodified form and the 14.040 kDa
peak was recognized as the cysteinylated form. The 17.139
and 17.256 kDa peaks were recognized as dimers of apol-
ipoprotein A-II (Apo A-II), the 8.609 and 4.401 kDa peaks
were recognized as truncated forms of Apo A-II, and the
6.428 and 3.212 kDa peaks were recognized as truncated
forms of Apo C-I. To verify the identities of the two most
discriminating proteins we performed serum depletion
experiments using specific antibodies and MS protein
identification.
An anti-human transthyretin antibody depleted both a
12.865 kDa peak, formerly identified as a fragment of
transthyretin [11], and a group of peaks around 14 kDa,
including the 13.877 and 14.040 serum peaks (Figure 4).
Using the anti-Apo A-II antibody, we were not able to
deplete any peaks. However, when the quality of the anti-
body was checked by SELDI-TOF we found very low
amounts of full-length antibodies and high levels of light
and heavy chains. Therefore, serum fraction 6 was sepa-
rated on a 1D SDS PAGE and bands in the area around 17
kDa where cut out, trypsin digested and the resultant sam-
ples underwent MS identification. The result indicated
that the samples were not pure. After common impurities
like keratin had been excluded, there were eight potential
proteins left for evaluation. The proteins were in the fol-
lowing order based on the number of assigned peptides:
Apo A-II, serum amyloid A 4, hemoglobin subunit alpha,
Apo A-I, hemoglobin subunit beta, transthyretin, histone
H4 and albumin. Apo A-II had the highest number of
Change in mean peak intensities Figure 3
Change in mean peak intensities. Change in mean peak intensity (thick line) ± SEM during the first year of GH treatment 
(left panels), before the start (middle panels) after 1 year of treatment (right panels) for the 13.788 and the 17.139 kDa peaks 
that were most predictive for discrimination between children with a high (red) or low (blue) growth response to treatment.
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assigned peptides. The MS identification results, together
with the characteristic serum profile pattern, strongly sug-
gest that the 17.139 and 17.256 kDa peaks represent Apo
A-II.
Discussion
The present study utilized a pharmaco-proteomic
approach in order to identify novel biomarkers that can
be used to predict growth in response to GH treatment in
short prepubertal children with idiopathic short stature.
Using this approach we identified two peaks that together
enabled the correct classification of 82% of the study sub-
jects as either good or poor responders to GH treatment.
Through further analysis, using a combination of the spe-
cific peak patterns within the spectra, results from serum-
depletion experiments and MS identification, we identi-
fied these peaks to represent transthyretin and Apo A-II.
One of the two most discriminatory peaks in the present
study was the unmodified form of transthyretin, also
known as prealbumin. In addition to its functions as a car-
rier of serum thyroxine and triiodothyronine and a trans-
porter of retinol [12], transthyretin is known as a marker
of nutrition. Studies have shown that in cases of malnutri-
tion there is a poor growth response to GH [13]. Clinical
studies also show that a high leptin level, a marker of adi-
pocyte tissue mass, at start of GH treatment correlates with
a better growth response [14]. The intensity of the tran-
sthyretin peak increased in the low-responder group and
decreased in the high-responder group during GH treat-
ment. Interestingly, GH administration has also been
shown to increase serum levels of transthyretin in severely
burned children and in adults after hepatectomy [15,16],
suggesting a common mechanism between serious illness
and low GH responsiveness. Our results are in line with a
report showing that serum levels of transthyretin in rats
were markedly decreased by hypophysectomy and further
decreased after GH replacement [17]. Furthermore, tran-
sthyretin has been shown to play a role in type 1 diabetes.
Patients with type 1 diabetes had lower serum levels of
transthyretin than healthy controls. In addition, the tran-
sthyretin tetramer, in contrast to the transthyretin mono-
mer, promoted insulin release [18].
The second most predictive peak was Apo A-II. This peak
remained unchanged in the low responders, but decreased
in the high responders after GH treatment. Apo A-II is the
second most abundant protein component of high-den-
sity lipoprotein (HDL)-cholesterol but little is known
about its role in HDL metabolism. GH plays a role in lipid
and lipoprotein metabolism in man, increasing both the
uptake and degradation of low-density lipoproteins [19].
A study of GH-deficient children suggested that GH had
no effect on serum Apo A-II levels [20]. Experiments using
Depletion of transthyretin from serum using specific anti-transthyretin antibodies Figure 4
Depletion of transthyretin from serum using specific anti-transthyretin antibodies. The upper panel represents the 
depleted serum and the lower panel represents the original sera before depletion. The peak with the molecular mass of 13.877 
kDa is indicated by an arrow.
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mouse models have shown a role for Apo A-II in glucose
homeostasis: Apo A-II-deficient mice showed improved
insulin sensitivity, whereas transgenic mice over-express-
ing murine Apo A-II showed insulin resistance and obes-
ity [21]. Apo A-II has also been suggested as a candidate
gene in type 2 diabetes [22-24].
Using rotated two-component PLS regression and PLS dis-
criminant analysis, we have shown that the protein peak
corresponding to transthyretin correlates with auxological
data as shown in Figure 2. Moreover, apolipoprotein lev-
els appear to correlate with changes in the GH/IGF/leptin
axis. This could partly explain the influence of nutrition
on GH responsiveness. However, our results must be val-
idated on an independent patient sample.
In this study we analyzed serum protein profiles from
before the start of GH treatment and after 1 year of treat-
ment. This time period was selected as growth response
during 1 year has been shown to give an estimate of GH
responsiveness, known as the response score. We were
interested to see whether changes during this time period
in the expression of the novel biomarkers identified could
be of additional value in predicting long term prepubertal
growth [25,26].
In order to predict the growth response to GH treatment,
it is preferable to be able to use pre-treatment data. From
the protein profiles before the start of treatment we were
able to create a model based on the intensity levels of
three peaks. However, this model was not as robust as the
model for changes in response to GH treatment. The opti-
mal time period needed to ascertain changes that may be
of utility in predicting final height is certain different for
different variables. For example, we know that short-term
changes in serum IGF-I levels are a better predictor of
growth response than serum levels of IGF-I before the start
of treatment [27]. In this context, it would also be of inter-
est to analyze short-term changes in protein profiles after
the start of treatment, for example after 1–2 weeks.
SELDI-TOF is a complementary technology to other pro-
teomic techniques like 2D gel electrophoresis; for our pur-
poses, a major advantage is that SELDI-TOF is a high
throughput technique and is therefore more suitable for
analyzing a large quantity of samples than 2D gel electro-
phoresis. Furthermore, SELDI-TOF technology has an
improved sensitivity in the mass range < 25 kDa, whereas
2D electrophoresis has a high resolution and sensitivity
between 20 and 150 kDa. The reproducibility and reliabil-
ity of the SELDI-TOF-MS proteomic system have been dis-
cussed [28-30]. Transit time, storage conditions, clotting
time and tube type used can affect protein profiles
[31,32], which has raised concerns about using samples
from retrospective studies. However, proper handling of
samples can minimize these shortcomings [33], and in
the present study we took special precautions to ascertain
standardization. Samples were stored at -70°C and were
not thawed until used for analysis. They were randomized
to each bioprocessor and the analyses were run within a
week by the same operator. A reference sample was
applied on each array. Using PCA, PLS regression and
stepwise regression, we did not detect systematic errors
correlated with non-GH-dependent factors or instrumen-
tal biases such as array or spot number, but for some peaks
we found a weak linear relationship between peak inten-
sity and storage time, which was adjusted for in all data
analyses. Two peaks with a non-linear relationship to stor-
age time were excluded from further analysis. The average
CV of 18% for 17 peaks in the reference samples was in
the expected range for this method [34].
In order to find peaks related to GH responsiveness we
used an integrated strategy, combining the results from
cross-validated stepwise regressions and PLS regressions.
The best distinction between good and poor responders
over the first year of GH treatment was obtained using two
peaks; adding more peaks into the model increased back-
ground noise.
Reciprocal relationships between the most predictive
peaks were visualized with rotated PLS regression to
explore the formation of clusters of peaks containing
comparable information. As the target response variable,
we explored the prediction of the binary low/high
response and the first year growth response in height SD
score; results were similar.
Only one previous study has utilized SELDI-TOF pro-
teomics to search for GH-dependent biomarkers [35]. In
this study the aim was to identify novel biomarkers of GH
administration in adult athletes. A peak of 15.1 kDa was
identified as the most effective classifier of subjects receiv-
ing GH. This peak was identified as hemoglobin α-chain
(HbA1). We did not identify this peak to be influenced by
GH treatment in short children, possibly due to the differ-
ent study groups and different ProteinChip surfaces that
were utilized in the two studies.
From the information of isoelectric points, the known
GH-dependent proteins IGF-I, IGFBP-3, leptin and insu-
lin are not expected to be identified in protein profiles
from serum fraction 6 on CM10 arrays. IGF-I is expected
to be detected in fraction 1, and IGFBP-3, leptin and insu-
lin are expected to be detected in fraction 3. In the pilot
study of four good and four poor responders, performed
with all fractions on three array surfaces, a 7.643 kDa peak
corresponding to the mass of IGF-I, was detected on
CM10 arrays in fraction 1. This peak was up-regulated by
70% during the first year of GH treatment in the high-Proteome Science 2008, 6:35 http://www.proteomesci.com/content/6/1/35
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responder group, whereas there was no significant change
in peak intensity in the low-responder group.
In summary, we have shown that analysis of serum pro-
tein expression patterns can be a useful method for iden-
tifying novel markers of GH responsiveness. In future,
knowledge obtained using broad exploratory techniques,
could possibly be used in the development of new clinical
tools for diagnosis and treatment.
Conclusion
In this study we show that a pharmaco-proteomic
approach can be used in order to identify novel biomark-
ers that can be used to discriminate between good and
poor responders to GH treatment among short prepuber-
tal children with ISS. Optimal results were obtained when
changes in peak intensity during first year of treatment
were analyzed. Using this approach we identified two
peaks that together enabled the correct classification of
82% of the study subjects as either good or poor respond-
ers to GH treatment. Through further analysis, using a
combination of the specific peak patterns within the spec-
tra, results from serum-depletion experiments and MS
identification, these peaks were identified to represent
transthyretin and Apo A-II. These results suggest that these
proteins may have a role in determining GH sensitivity.
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